IS7328A - Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum - Google Patents

Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum

Info

Publication number
IS7328A
IS7328A IS7328A IS7328A IS7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A
Authority
IS
Iceland
Prior art keywords
aerokinases
inhibit
replaced
quinazoline derivatives
quinazoline
Prior art date
Application number
IS7328A
Other languages
English (en)
Other versions
IS2758B (is
Inventor
Henri Jung Frederic
Rene Pasquet Georges
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7328A publication Critical patent/IS7328A/is
Publication of IS2758B publication Critical patent/IS2758B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
IS7328A 2001-12-24 2004-06-21 Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum IS2758B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403357 2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en) 2001-12-24 2002-12-20 Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (2)

Publication Number Publication Date
IS7328A true IS7328A (is) 2004-06-21
IS2758B IS2758B (is) 2011-10-15

Family

ID=8183051

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7328A IS2758B (is) 2001-12-24 2004-06-21 Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum

Country Status (32)

Country Link
US (2) US7402585B2 (is)
EP (1) EP1463506B1 (is)
JP (1) JP4498741B2 (is)
KR (1) KR101029281B1 (is)
CN (1) CN100491372C (is)
AR (1) AR038052A1 (is)
AT (1) ATE446093T1 (is)
AU (1) AU2002353196B2 (is)
BR (1) BRPI0215312B8 (is)
CA (1) CA2471577C (is)
CY (1) CY1109681T1 (is)
DE (1) DE60234125D1 (is)
DK (1) DK1463506T3 (is)
ES (1) ES2333702T3 (is)
HK (1) HK1076598A1 (is)
HU (1) HU229477B1 (is)
IL (1) IL162541A0 (is)
IS (1) IS2758B (is)
MX (1) MXPA04006260A (is)
MY (1) MY141739A (is)
NO (1) NO328159B1 (is)
NZ (1) NZ533440A (is)
PL (1) PL211694B1 (is)
PT (1) PT1463506E (is)
RU (1) RU2323215C2 (is)
SA (1) SA03230531B1 (is)
SI (1) SI1463506T1 (is)
TW (1) TWI335818B (is)
UA (1) UA82058C2 (is)
UY (1) UY27604A1 (is)
WO (1) WO2003055491A1 (is)
ZA (1) ZA200404923B (is)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
KR101010299B1 (ko) * 2002-12-24 2011-01-25 아스트라제네카 아베 포스포노옥시 퀴나졸린 유도체 및 이의 약학적 용도
ES2301981T3 (es) 2003-04-16 2008-07-01 Astrazeneca Ab Derivados de quinazolina para el tratamiento del cancer.
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
ATE437872T1 (de) 2003-10-14 2009-08-15 Univ Arizona Proteinkinaseinhibitoren
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
ES2374553T3 (es) 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-fenilamino-quinazolin-6-il-amidas.
JP2008506714A (ja) * 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼインヒビターとして有用なチエノピリミジン
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
TW200624431A (en) * 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
NZ554017A (en) 2004-10-12 2010-06-25 Astrazeneca Ab [(Quinazolin-4-yloxy)phenyl]acetamide derivatives
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
CA2607727A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
EP1915377A1 (en) * 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
MX2008011769A (es) * 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
EP2040711A2 (en) * 2006-05-18 2009-04-01 Amphora Discovery Corporation 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008041767A1 (fr) 2006-10-05 2008-04-10 Banyu Pharmaceutical Co., Ltd. Marqueur de gène ou de protéine utilisé pour la prévision ou le diagnostic de l'efficacité pharmacologique d'un inhibiteur d'aurora a
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
JP2010532381A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な複素環式化合物
EP2262796A1 (en) 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US8637532B2 (en) * 2009-02-11 2014-01-28 Merck Patent Gmbh Amino azaheterocyclic carboxamides
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465842A1 (de) * 2010-12-17 2012-06-20 Sika Technology AG Amine mit sekundären aliphatischen Aminogruppen
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
US9650364B2 (en) 2013-02-21 2017-05-16 GlaxoSmithKline Intellectual Property Development Limted Quinazolines as kinase inhibitors
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
MX370490B (es) 2013-09-16 2019-12-16 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
EP3122358B1 (en) 2014-03-26 2020-12-16 Astex Therapeutics Ltd. Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SI3353177T1 (sl) 2015-09-23 2020-08-31 Janssen Pharmaceutica Nv Triciklični heterocikli za zdravljenje raka
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
WO2000021955A1 (en) * 1998-10-08 2000-04-20 Astrazeneca Ab Quinazoline derivatives
DE60043349D1 (de) * 1999-09-21 2009-12-31 Astrazeneca Ab Chinazolin-derivate und ihre verwendung als arzneimittel
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB0006864D0 (en) * 2000-03-21 2000-05-10 Smithkline Beecham Plc New use
EP1299381B1 (en) * 2000-06-28 2008-05-07 AstraZeneca AB Substituted quinazoline derivatives and their use as inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
US7105425B1 (en) * 2002-05-16 2006-09-12 Advanced Micro Devices, Inc. Single electron devices formed by laser thermal annealing
KR101010299B1 (ko) * 2002-12-24 2011-01-25 아스트라제네카 아베 포스포노옥시 퀴나졸린 유도체 및 이의 약학적 용도
ES2301981T3 (es) * 2003-04-16 2008-07-01 Astrazeneca Ab Derivados de quinazolina para el tratamiento del cancer.
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2006040526A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives for use against cancer
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
US20080194556A1 (en) * 2005-05-28 2008-08-14 Astrazeneca Ab Quinazolines and Their Use as Aurora Kinase Inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
JP2011506420A (ja) * 2007-12-12 2011-03-03 アストラゼネカ アクチボラグ Ｍｅｋ阻害剤及びオーロラキナーゼ阻害剤１８８を含んでなる組合せ

Also Published As

Publication number Publication date
EP1463506B1 (en) 2009-10-21
MY141739A (en) 2010-06-15
RU2323215C2 (ru) 2008-04-27
BR0215312A (pt) 2004-12-07
IL162541A0 (en) 2005-11-20
CY1109681T1 (el) 2014-08-13
DK1463506T3 (da) 2010-01-11
MXPA04006260A (es) 2005-03-31
SA03230531B1 (ar) 2008-09-08
AR038052A1 (es) 2004-12-22
NZ533440A (en) 2006-08-31
KR20040066929A (ko) 2004-07-27
EP1463506A1 (en) 2004-10-06
JP2005525307A (ja) 2005-08-25
BRPI0215312B8 (pt) 2021-05-25
UY27604A1 (es) 2003-07-31
CA2471577A1 (en) 2003-07-10
TWI335818B (en) 2011-01-11
AU2002353196A1 (en) 2003-07-15
WO2003055491A1 (en) 2003-07-10
NO20043158L (no) 2004-09-16
US7402585B2 (en) 2008-07-22
RU2004122926A (ru) 2005-07-10
PL371253A1 (en) 2005-06-13
ATE446093T1 (de) 2009-11-15
HUP0402454A3 (en) 2009-08-28
US20050070561A1 (en) 2005-03-31
SA03230531A (ar) 2005-12-03
TW200410697A (en) 2004-07-01
PL211694B1 (pl) 2012-06-29
IS2758B (is) 2011-10-15
ZA200404923B (en) 2005-11-30
DE60234125D1 (de) 2009-12-03
HUP0402454A2 (hu) 2005-03-29
CN1620296A (zh) 2005-05-25
HK1076598A1 (en) 2006-01-20
CN100491372C (zh) 2009-05-27
BRPI0215312B1 (pt) 2018-03-27
AU2002353196B2 (en) 2008-01-17
SI1463506T1 (sl) 2010-01-29
CA2471577C (en) 2011-08-02
PT1463506E (pt) 2009-12-10
NO328159B1 (no) 2009-12-21
US20090215770A1 (en) 2009-08-27
UA82058C2 (uk) 2008-03-11
ES2333702T3 (es) 2010-02-26
HU229477B1 (en) 2014-01-28
KR101029281B1 (ko) 2011-04-18
JP4498741B2 (ja) 2010-07-07

Similar Documents

Publication Publication Date Title
IS7328A (is) Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
IS7240A (is) Kínasólínafleiður sem æxliseyðandi efni
IS7241A (is) Kínasólínafleiður sem æxliseyðandi efni
IS6886A (is) Kínasólín sem MMP-13 hindrar
IS7362A (is) Kínasólín efnasambönd
DK1847539T3 (da) Quinazolin-derivater
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
DK1671949T3 (da) Substituerede pyridinylaminer
IS6298A (is) Teridínón sem tálmar kínasa
IS6971A (is) Ný efnasambönd
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE50206892D1 (de) Substituierte imidazotriazinone
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
NO20035573L (no) Kinazolinderivater
DE60239393D1 (de) Verriegelungsanordnung
DE60231830D1 (de) Verriegelungsanordnung
DE50202174D1 (de) Schliesszylinder
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE60203764D1 (de) Flachprofil-Wegwerfpolymerkapillarkissen
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE60216967D1 (de) Substituierte cyclohexanderivate
FI4977U1 (fi) Lukituslaite
SE0100694D0 (sv) DHFR inhibitors